Targets › GNRH1
3 programs from 3 companies in 3 trials: 3 Phase 3; Other, Oncology, Metabolic and endocrine; next expected readout Jan 2027.
[Gonadoliberin-1]: Hypothalamic decapeptide hormone that functions as the master regulator of the hypothalamic-pituitary-gonadal axis. Released in a pulsatile manner from hypothalamic neuron terminals into the hypophyseal portal circulation, it acts on pituitary gonadotrope cells by binding to and activating its cognate G protein-coupled receptor GNRHR, thereby stimulating the synthesis and secretion of the…. (UniProt, P01148)
Open in Phaseline: the race on GNRH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tolmar | TOL2506 GnRH receptor agonist for ovarian suppression | GNRH1 | Phase 3 | Breast Cancer | Jan 2027 |
| Assistance Publique - Hôpitaux de Paris | Nafarelin GnRH agonist for luteal phase support | GNRH1 | Phase 3 | In Vitro Fertilization | Sep 2027 |
| Debiopharm International | Debio 4326 GnRH receptor agonist | GNRH1 | Phase 3 | Central Precocious Puberty | Feb 2028 |
In Vitro Fertilization (1) Breast Cancer (1) Central Precocious Puberty (1)
small molecule (2), protein or peptide (1)
Assistance Publique - Hôpitaux de Paris (1) Tolmar (1) Debiopharm International (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.